The therapeutic community is buzzing with anticipation surrounding retatrutide, a novel dual GIP and GLP-1 target that’s demonstrating significant efficacy in clinical trials for managing obesity. Unlike some current weight loss treatments, retatrutide appears to offer a significant substantial reduction in body weight and benefit metabolic marke